N S Russell
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015
13.10.2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
13.10.2015Ann Oncol 2015
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.
27.02.2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
27.02.2015Ann Oncol 2015; 26:873-9
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S